- Home
- VRRM vs TGTX Comparison
VRRM vs TGTX Comparison
Compare VRRM & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRRM
- TGTX
- Stock Information
- Founded
- VRRM 1987
- TGTX 1993
- Country
- VRRM United States
- TGTX United States
- Employees
- VRRM N/A
- TGTX N/A
- Industry
- VRRM Transportation Services
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRRM Consumer Discretionary
- TGTX Health Care
- Exchange
- VRRM Nasdaq
- TGTX Nasdaq
- Market Cap
- VRRM 4.0B
- TGTX 4.2B
- IPO Year
- VRRM N/A
- TGTX 1995
- Fundamental
- Price
- VRRM $25.54
- TGTX $29.45
- Analyst Decision
- VRRM Strong Buy
- TGTX Strong Buy
- Analyst Count
- VRRM 4
- TGTX 4
- Target Price
- VRRM $27.88
- TGTX $42.50
- AVG Volume (30 Days)
- VRRM 1.0M
- TGTX 2.9M
- Earning Date
- VRRM 08-06-2025
- TGTX 08-04-2025
- Dividend Yield
- VRRM N/A
- TGTX N/A
- EPS Growth
- VRRM N/A
- TGTX N/A
- EPS
- VRRM 0.24
- TGTX 0.36
- Revenue
- VRRM $906,330,000.00
- TGTX $454,069,000.00
- Revenue This Year
- VRRM $7.87
- TGTX $84.00
- Revenue Next Year
- VRRM $7.44
- TGTX $39.26
- P/E Ratio
- VRRM $103.72
- TGTX $81.62
- Revenue Growth
- VRRM 6.24
- TGTX 30.96
- 52 Week Low
- VRRM $19.51
- TGTX $21.11
- 52 Week High
- VRRM $28.25
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VRRM 60.92
- TGTX 42.03
- Support Level
- VRRM $24.07
- TGTX $27.23
- Resistance Level
- VRRM $24.45
- TGTX $28.85
- Average True Range (ATR)
- VRRM 0.61
- TGTX 1.11
- MACD
- VRRM 0.09
- TGTX 0.29
- Stochastic Oscillator
- VRRM 99.08
- TGTX 99.05
About VRRM Verra Mobility Corporation
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three segments namely Commercial Services, Government Solutions, and Parking Solutions. It generates maximum revenue from the Commercial Services segment. The commercial Services segment delivers tolling and violation management services to rental car companies, commercial fleet vehicle owners, and violation issuing authorities.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.